Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins

Molecular Carcinogenesis

Volumn 50, Issue 9, 2011, Pages 655-667

  Chintharlapalli, Sudhakar ^a   Papineni, Sabitha ^a,b   Lee, Syng Ook ^a   Lei, Ping ^a   Jin, Un Ho ^a   Sherman, Steven I ^c   Santarpia, Libero ^c   Safe, Stephen ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer agents; PTTG 1; Sp proteins; Thyroid cancer

Indexed keywords

2 TRIFLUOROMETHYL DERIVATIVE; MESSENGER RNA; METHYL 2 CYANO 3,11 DIOXO 18BETA OLEAN 1,12 DIEN 30 OATE; SECURIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; TRITERPENOID; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE; THYROID CANCER;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FLUORINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCYRRHETINIC ACID; HUMANS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; THYROID NEOPLASMS;

GLYCYRRHIZA;

EID: 79960644927     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20738     Document Type: Article

References (50)

1. Dominguez A, Ramos-Morales F, Romero F, et al. hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 1998; 17: 2187-2193.
2. Kim DS, Fong J, Read ML, McCabe CJ. The emerging role of pituitary tumour transforming gene (PTTG) in endocrine tumourigenesis. Mol Cell Endocrinol 2007; 278: 1-6.
3. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: Physiology and implications for tumorigenesis. Endocr Rev 2007; 28: 165-186.
4. Pei L. Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 2001; 276: 8484-8491.
5. Boelaert K, Yu R, Tannahill LA, et al. PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol 2004; 33: 663-677.
6. Tong Y, Tan Y, Zhou C, Melmed S. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 2007; 26: 5596-5605.
7. Wang Z, Yu R, Melmed S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 2001; 15: 1870-1879.
8. Wang Z, Moro E, Kovacs K, Yu R, Melmed S. Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci USA 2003; 100: 3428-3432.
9. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S. Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol 2005; 19: 2371-2379.
10. Abbud RA, Takumi I, Barker EM, et al. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 2005; 19: 1383-1391.
11. Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84: 761-767.
12. Saez C, Japon MA, Ramos-Morales F, et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 1999; 18: 5473-5476.
13. Boelaert K, McCabe CJ, Tannahill LA, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: Potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 2003; 88: 2341-2347.
14. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: A prognostic marker for lymph node invasion and tumor recurrence. Breast 2004; 13: 80-81.
15. Thompson AD III, Kakar SS. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 2005; 579: 3195-3200.
16. Rehfeld N, Geddert H, Atamna A, et al. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog 2006; 5: 4.
17. Hlubek F, Pfeiffer S, Budczies J, et al. Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer 2006; 94: 1672-1677.
18. Saez C, Martinez-Brocca MA, Castilla C, et al. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab 2006; 91: 1404-1409.
19. Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP. Securin is overexpressed in breast cancer. Mod Pathol 2005; 18: 985-990.
20. Shibata Y, Haruki N, Kuwabara Y, et al. Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 2002; 32: 233-237.
21. Heaney AP, Singson R, McCabe CJ, et al. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000; 355: 716-719.
22. Cho-Rok J, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006; 43: 1042-1052.
23. Kim DS, Franklyn JA, Stratford AL, et al. Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. J Clin Endocrinol Metab 2006; 91: 1119-1128.
24. Kakar SS, Malik MT. Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol 2006; 29: 387-395.
25. Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003; 9: 6371-6380.
26. Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10: 4109-4117.
27. Shi Q, Le X, Abbruzzese JL, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 4143-4154.
28. Zannetti A, Del VS, Carriero MV, et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000; 60: 1546-1551.
29. Chiefari E, Brunetti A, Arturi F, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: A role in NIS expression regulation? BMC Cancer 2002; 2: 35.
30. 2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001-11011.
31. Jiang NY, Woda BA, Banner BF, et al. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 1648-1652.
32. Abdelrahim M, Smith R III, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004; 64: 6740-6749.
33. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 (VEGFR1) expression by specificity proteins 1, 3 and 4 in pancreatic cancer cells. Cancer Res 2007; 67: 3286-3294.
34. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 2006; 345: 292-301.
35. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997; 15: 669-676.
36. Li Y, Xie M, Yang J, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006; 25: 3296-3306.
37. Wu J, Ling X, Pan D, et al. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: Evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 2005; 280: 9745-9751.
38. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67: 2816-2823.
39. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006; 98: 855-868.
40. Chintharlapalli S, Papineni S, Abdelrahim M, et al. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3, 11-dioxo-18b-olean-1, 12-dien-30-oate in colon cancer cells. Int J Cancer 2009; 125: 1965-1974.
41. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008; 68: 5345-5354.
42. Chadalapaka G, Jutooru I, McAlees A, Stefanac T, Safe S. Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives. Bioorg Med Chem Lett 2008; 18: 2633-2639.
43. Clem AL, Hamid T, Kakar SS. Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 2003; 322: 113-121.
44. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008; 93: 4331-4341.
45. Chen RN, Huang YH, Yeh CT, Liao CH, Lin KH. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res 2008; 68: 1697-1706.
46. Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expession in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005; 68: 317-329.
47. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-2448.
48. Oh JE, Han JA, Hwang ES. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun 2007; 353: 86-91.
49. Papineni S, Chintharlapalli S, Abdelrahim M, et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009; 30: 1193-1201.
50. Papineni S, Chintharlapalli S, Safe S. Methyl 2-cyano-3, 11-dioxo-18b-olean-1, 12-dien-30-oate is a peroxisome proliferator-activated receptor γ agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells. Mol Pharmacol 2008; 73: 553-565.